MEDOXICAM TAB 7,5MG/TAB Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

medoxicam tab 7,5mg/tab

medochemie hellas ae ΠΑΡΑΣ.& ΕΜΠΟΡ.ΦΑΡΜ.& Φ/ΚΩΝ ΠΡ. Δ.Τ. medochemie hellas a.e. Παστέρ 6,, 115 21 115 21, Αθήνα 210.6413160 - meloxicam - tab (ΔΙΣΚΙΟ) - 7,5mg/tab - meloxicam 7,5mg - meloxicam

MEDOXICAM TAB 15MG/TAB Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

medoxicam tab 15mg/tab

medochemie hellas ae ΠΑΡΑΣ.& ΕΜΠΟΡ.ΦΑΡΜ.& Φ/ΚΩΝ ΠΡ. Δ.Τ. medochemie hellas a.e. Παστέρ 6,, 115 21 115 21, Αθήνα 210.6413160 - meloxicam - tab (ΔΙΣΚΙΟ) - 15mg/tab - meloxicam 15mg - meloxicam

MEDOXICAM INJ.SOL 15MG/1,5ML AMP Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

medoxicam inj.sol 15mg/1,5ml amp

medochemie hellas ae ΠΑΡΑΣ.& ΕΜΠΟΡ.ΦΑΡΜ.& Φ/ΚΩΝ ΠΡ. Δ.Τ. medochemie hellas a.e. Παστέρ 6,, 115 21 115 21, Αθήνα 210.6413160 - meloxicam - inj.sol (ΕΝΕΣΙΜΟ ΔΙΑΛΥΜΑ) - 15mg/1,5ml amp - meloxicam 15mg - meloxicam

ETHRINE 25MG/TAB C.TAB Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

ethrine 25mg/tab c.tab

biomedica ae - dipyridamole - ΕΠΙΚΑΛΥΜΕΝΟ ΔΙΣΚΙΟ - 25mg/tab - ΦΑΡΜΑΚΕΥΤΙΚΟ ΠΡΟΪΟΝ

ETHRINE 75MG/TAB C.TAB Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

ethrine 75mg/tab c.tab

biomedica ae - dipyridamole - ΕΠΙΚΑΛΥΜΕΝΟ ΔΙΣΚΙΟ - 75mg/tab - ΦΑΡΜΑΚΕΥΤΙΚΟ ΠΡΟΪΟΝ

Vegzelma Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

vegzelma

celltrion healthcare hungary kft. - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - Αντινεοπλασματικοί παράγοντες - vegzelma in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. vegzelma in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. Για περισσότερες πληροφορίες σχετικά με την κατάσταση του υποδοχέα 2 του ανθρώπινου επιδερμικού αυξητικού παράγοντα (her2), παρακαλούμε ανατρέξτε στην ενότητα 5. vegzelma in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with vegzelma in combination with capecitabine. Για περισσότερες πληροφορίες σχετικά με την κατάσταση her2, ανατρέξτε στην ενότητα 5. vegzelma, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer (nsclc) other than predominantly squamous cell histology. vegzelma, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent nsclc with epidermal growth factor receptor (egfr) activating mutations (see section 5. vegzelma, in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. vegzelma, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. vegzelma, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vascular endothelial growth factor (vegf) inhibitors or vegf receptor–targeted agents. vegzelma in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents (see section 5. vegzelma, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.

Byannli (previously Paliperidone Janssen-Cilag International) Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

byannli (previously paliperidone janssen-cilag international)

janssen-cilag international n.v.   - παλμιτική παλιπεριδόνη - Σχιζοφρένεια - Ψυχοληπτικά - byannli (previously paliperidone janssen-cilag international) a 6 monthly injection, is indicated for the maintenance treatment of schizophrenia in adult patients who are clinically stable on 1 monthly or 3 monthly paliperidone palmitate injectable products (see section 5.